Erlotinib Active Not Recruiting Phase 2 Trials for Bladder Cancers Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00380029Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer